Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.

Gittleman H, Cioffi G, Chunduru P, Molinaro AM, Berger MS, Sloan AE, Barnholtz-Sloan JS.

Neurooncol Adv. 2019 May-Dec;1(1):vdz007. doi: 10.1093/noajnl/vdz007. Epub 2019 May 30.

2.

An independently validated survival nomogram for lower grade glioma.

Gittleman H, Sloan AE, Barnholtz-Sloan JS.

Neuro Oncol. 2019 Oct 17. pii: noz191. doi: 10.1093/neuonc/noz191. [Epub ahead of print]

PMID:
31621885
3.

An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.

Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJC, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS.

Neuro Oncol. 2017 May 1;19(5):669-677. doi: 10.1093/neuonc/now208.

4.

Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.

Saito T, Sugiyama K, Hama S, Yamasaki F, Takayasu T, Nosaka R, Muragaki Y, Kawamata T, Kurisu K.

Neurosurg Rev. 2018 Apr;41(2):621-628. doi: 10.1007/s10143-017-0903-3. Epub 2017 Sep 9.

PMID:
28887717
5.
6.

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.

Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K.

Acta Neuropathol Commun. 2016 Aug 8;4(1):79. doi: 10.1186/s40478-016-0351-2.

7.

Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.

Molitoris JK, Rao YJ, Patel RA, Kane LT, Badiyan SN, Gittleman H, Barnholtz-Sloan JS, Bentzen SM, Kruser TJ, Huang J, Mehta MP.

J Neurooncol. 2017 Sep;134(2):331-338. doi: 10.1007/s11060-017-2529-2. Epub 2017 Jun 22.

PMID:
28643151
8.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
9.

DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.

Etcheverry A, Aubry M, Idbaih A, Vauleon E, Marie Y, Menei P, Boniface R, Figarella-Branger D, Karayan-Tapon L, Quillien V, Sanson M, de Tayrac M, Delattre JY, Mosser J.

PLoS One. 2014 Sep 18;9(9):e104455. doi: 10.1371/journal.pone.0104455. eCollection 2014.

10.

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R.

Lancet Oncol. 2008 Jan;9(1):29-38. Epub 2007 Dec 21.

PMID:
18082451
11.

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme.

Greer L, Pannullo SC, Smith AW, Taube S, Yondorf MZ, Parashar B, Trichter S, Nedialkova L, Sabbas A, Christos P, Wernicke AG.

Cureus. 2017 Jun 24;9(6):e1388. doi: 10.7759/cureus.1388.

12.

Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.

Karsy M, Guan J, Huang LE.

J Neurosurg. 2018 Mar 16;130(1):56-66. doi: 10.3171/2017.9.JNS172036.

PMID:
29547090
13.

Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.

Ayoub Z, Geara F, Najjar M, Comair Y, Khoueiry-Zgheib N, Khoueiry P, Mahfouz R, Boulos FI, Kamar FG, Andraos T, Saadeh F, Kreidieh F, Abboud M, Skaf G, Assi HI.

Clin Neurol Neurosurg. 2019 Jul;182:92-97. doi: 10.1016/j.clineuro.2019.04.008. Epub 2019 Apr 29.

PMID:
31108342
14.

Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study.

Roh TH, Kang SG, Moon JH, Sung KS, Park HH, Kim SH, Kim EH, Hong CK, Suh CO, Chang JH.

J Neurosurg. 2019 Mar 1:1-7. doi: 10.3171/2018.12.JNS182558. [Epub ahead of print]

PMID:
30835701
15.

Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.

Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.

J Neurosurg. 2014 Sep;121(3):543-53. doi: 10.3171/2014.5.JNS132392. Epub 2014 Jul 4.

PMID:
24995786
16.

Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?

Tanaka S, Akimoto J, Narita Y, Oka H, Tashiro T.

J Neurosurg. 2014 Oct;121(4):818-26. doi: 10.3171/2014.6.JNS132535. Epub 2014 Aug 8.

PMID:
25105699
17.

Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.

Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U, Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M.

Neurology. 2017 Apr 11;88(15):1422-1430. doi: 10.1212/WNL.0000000000003809. Epub 2017 Mar 15.

18.

Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma.

Thomas JG, Rao G, Kew Y, Prabhu SS.

Neurosurg Focus. 2016 Oct;41(4):E12.

PMID:
27690657
19.

A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.

Woo P, Ho J, Lam S, Ma E, Chan D, Wong WK, Mak C, Lee M, Wong ST, Chan KY, Poon WS.

World Neurosurg. 2018 Jul;115:e375-e385. doi: 10.1016/j.wneu.2018.04.059. Epub 2018 Apr 17.

PMID:
29678708
20.

MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?

Yamashita S, Yokogami K, Matsumoto F, Saito K, Mizuguchi A, Ohta H, Takeshima H.

J Neurosurg. 2018 May 4;130(3):780-788. doi: 10.3171/2017.11.JNS171710.

PMID:
29726772

Supplemental Content

Support Center